Léon Tshilolo1, George Tomlinson1, Thomas N Williams1, Brígida Santos1, Peter Olupot-Olupot1, Adam Lane1, Banu Aygun1, Susan E Stuber1, Teresa S Latham1, Patrick T McGann1, Russell E Ware1. 1. From Centre Hospitalier Monkole, Kinshasa, Democratic Republic of Congo (L.T.); the Department of Medicine, University Health Network and Mt. Sinai Hospital, and the University of Toronto, Toronto (G.T.); the Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Program, Kilifi, Kenya (T.N.W.); the Department of Medicine, Imperial College London, London (T.N.W.); Hospital Pediátrico David Bernardino, Luanda, Angola (B.S.); Mbale Clinical Research Institute and Mbale Regional Referral and Teaching Hospital-Busitema University, Mbale, Uganda (P.O.-O.); the Division of Hematology, Department of Pediatrics, Cincinnati Children's Hospital (A.L., S.E.S., T.S.L., P.T.M., R.E.W.), University of Cincinnati College of Medicine (A.L., P.T.M., R.E.W.), and the Global Health Center, Cincinnati Children's Hospital Medical Center (S.E.S., P.T.M., R.E.W.), Cincinnati; and Cohen Children's Medical Center, New Hyde Park, and the Zucker School of Medicine at Hofstra/Northwell, Hempstead - both in New York (B.A.).
Abstract
BACKGROUND: Hydroxyurea is an effective treatment for sickle cell anemia, but few studies have been conducted in sub-Saharan Africa, where the burden is greatest. Coexisting conditions such as malnutrition and malaria may affect the feasibility, safety, and benefits of hydroxyurea in low-resource settings. METHODS: We enrolled children 1 to 10 years of age with sickle cell anemia in four sub-Saharan countries. Children received hydroxyurea at a dose of 15 to 20 mg per kilogram of body weight per day for 6 months, followed by dose escalation. The end points assessed feasibility (enrollment, retention, and adherence), safety (dose levels, toxic effects, and malaria), and benefits (laboratory variables, sickle cell-related events, transfusions, and survival). RESULTS: A total of 635 children were fully enrolled; 606 children completed screening and began receiving hydroxyurea at a mean (±SD) dose of 17.5±1.8 mg per kilogram per day. The retention rate was 94.2% at 3 years of treatment. Hydroxyurea therapy led to significant increases in both the hemoglobin and fetal hemoglobin levels. Dose-limiting toxic events regarding laboratory variables occurred in 5.1% of the participants, which was below the protocol-specified threshold for safety. During the treatment phase, 20.6 dose-limiting toxic effects per 100 patient-years occurred, as compared with 20.7 events per 100 patient-years before treatment. As compared with the pretreatment period, the rates of clinical adverse events decreased with hydroxyurea use, including rates of vaso-occlusive pain (98.3 vs. 44.6 events per 100 patient-years; incidence rate ratio, 0.45; 95% confidence interval [CI], 0.37 to 0.56), nonmalaria infection (142.5 vs. 90.0 events per 100 patient-years; incidence rate ratio, 0.62; 95% CI, 0.53 to 0.72), malaria (46.9 vs. 22.9 events per 100 patient-years; incidence rate ratio, 0.49; 95% CI, 0.37 to 0.66), transfusion (43.3 vs. 14.2 events per 100 patient-years; incidence rate ratio, 0.33; 95% CI, 0.23 to 0.47), and death (3.6 vs. 1.1 deaths per 100 patient-years; incidence rate ratio, 0.30; 95% CI, 0.10 to 0.88). CONCLUSIONS: Hydroxyurea treatment was feasible and safe in children with sickle cell anemia living in sub-Saharan Africa. Hydroxyurea use reduced the incidence of vaso-occlusive events, infections, malaria, transfusions, and death, which supports the need for wider access to treatment. (Funded by the National Heart, Lung, and Blood Institute and others; REACH ClinicalTrials.gov number, NCT01966731 .).
BACKGROUND:Hydroxyurea is an effective treatment for sickle cell anemia, but few studies have been conducted in sub-Saharan Africa, where the burden is greatest. Coexisting conditions such as malnutrition and malaria may affect the feasibility, safety, and benefits of hydroxyurea in low-resource settings. METHODS: We enrolled children 1 to 10 years of age with sickle cell anemia in four sub-Saharan countries. Children received hydroxyurea at a dose of 15 to 20 mg per kilogram of body weight per day for 6 months, followed by dose escalation. The end points assessed feasibility (enrollment, retention, and adherence), safety (dose levels, toxic effects, and malaria), and benefits (laboratory variables, sickle cell-related events, transfusions, and survival). RESULTS: A total of 635 children were fully enrolled; 606 children completed screening and began receiving hydroxyurea at a mean (±SD) dose of 17.5±1.8 mg per kilogram per day. The retention rate was 94.2% at 3 years of treatment. Hydroxyurea therapy led to significant increases in both the hemoglobin and fetal hemoglobin levels. Dose-limiting toxic events regarding laboratory variables occurred in 5.1% of the participants, which was below the protocol-specified threshold for safety. During the treatment phase, 20.6 dose-limiting toxic effects per 100 patient-years occurred, as compared with 20.7 events per 100 patient-years before treatment. As compared with the pretreatment period, the rates of clinical adverse events decreased with hydroxyurea use, including rates of vaso-occlusive pain (98.3 vs. 44.6 events per 100 patient-years; incidence rate ratio, 0.45; 95% confidence interval [CI], 0.37 to 0.56), nonmalaria infection (142.5 vs. 90.0 events per 100 patient-years; incidence rate ratio, 0.62; 95% CI, 0.53 to 0.72), malaria (46.9 vs. 22.9 events per 100 patient-years; incidence rate ratio, 0.49; 95% CI, 0.37 to 0.66), transfusion (43.3 vs. 14.2 events per 100 patient-years; incidence rate ratio, 0.33; 95% CI, 0.23 to 0.47), and death (3.6 vs. 1.1 deaths per 100 patient-years; incidence rate ratio, 0.30; 95% CI, 0.10 to 0.88). CONCLUSIONS:Hydroxyurea treatment was feasible and safe in children with sickle cell anemia living in sub-Saharan Africa. Hydroxyurea use reduced the incidence of vaso-occlusive events, infections, malaria, transfusions, and death, which supports the need for wider access to treatment. (Funded by the National Heart, Lung, and Blood Institute and others; REACH ClinicalTrials.gov number, NCT01966731 .).
Authors: S T Miller; L A Sleeper; C H Pegelow; L E Enos; W C Wang; S J Weiner; D L Wethers; J Smith; T R Kinney Journal: N Engl J Med Date: 2000-01-13 Impact factor: 91.245
Authors: P Pino; Z Taoufiq; M Brun; M Tefit; J F Franetich; L Ciceron; R Krishnamoorthy; D Mazier Journal: Parasite Immunol Date: 2006-12 Impact factor: 2.280
Authors: Martin H Steinberg; William F McCarthy; Oswaldo Castro; Samir K Ballas; F Danny Armstrong; Wally Smith; Kenneth Ataga; Paul Swerdlow; Abdullah Kutlar; Laura DeCastro; Myron A Waclawiw Journal: Am J Hematol Date: 2010-06 Impact factor: 10.047
Authors: Sherri A Zimmerman; William H Schultz; Jacqueline S Davis; Chrisley V Pickens; Nicole A Mortier; Thad A Howard; Russell E Ware Journal: Blood Date: 2003-11-20 Impact factor: 22.113
Authors: Courtney D Thornburg; Natalia Dixon; Shelly Burgett; Nicole A Mortier; William H Schultz; Sherri A Zimmerman; Melanie Bonner; Kristina K Hardy; Agustin Calatroni; Russell E Ware Journal: Pediatr Blood Cancer Date: 2009-05 Impact factor: 3.167
Authors: Paul Telfer; Pietro Coen; Subarna Chakravorty; Olu Wilkey; Jane Evans; Heather Newell; Beverley Smalling; Roger Amos; Adrian Stephens; David Rogers; Fenella Kirkham Journal: Haematologica Date: 2007-07 Impact factor: 9.941
Authors: Robert O Opoka; Heather A Hume; Teresa S Latham; Adam Lane; Olatundun Williams; Jennifer Tymon; Maria Nakafeero; Phillip Kasirye; Christopher M Ndugwa; Chandy C John; Russell E Ware Journal: Haematologica Date: 2019-10-24 Impact factor: 9.941
Authors: Muhammad Noman Hasan; Arwa Fraiwan; Ran An; Yunus Alapan; Ryan Ung; Asya Akkus; Julia Z Xu; Amy J Rezac; Nicholas J Kocmich; Melissa S Creary; Tolulope Oginni; Grace Mfon Olanipekun; Fatimah Hassan-Hanga; Binta W Jibir; Safiya Gambo; Anil K Verma; Praveen K Bharti; Suchada Riolueang; Takdanai Ngimhung; Thidarat Suksangpleng; Priyaleela Thota; Greg Werner; Rajasubramaniam Shanmugam; Aparup Das; Vip Viprakasit; Connie M Piccone; Jane A Little; Stephen K Obaro; Umut A Gurkan Journal: Analyst Date: 2020-03-03 Impact factor: 4.616